A NEW FRONTIER
TARGETING IBD.
It’s estimated that more than half of patients living with inflammatory bowel disease (IBD) are unable to achieve and maintain disease remission, despite currently available therapies.1 Through our research and development efforts, we are committed to the relentless pursuit of novel therapies that break through the efficacy ceiling as we strive to improve the lives of patients living with IBD.